Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: N/A
Symbol: NASDAQ:AGIO
CUSIP: N/A
Web: www.agios.com

Capitalization:

Market Cap: $2.8 billion
Outstanding Shares: 48,204,000

Average Prices:

50 Day Moving Avg: $53.89
200 Day Moving Avg: $50.36
52 Week Range: $35.84 - $67.74

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -10.27
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $49.12 million
Price / Sales: 57.04
Book Value: $7.25 per share
Price / Book: 8.02

Profitability:

EBIDTA: ($238,380,000.00)
Net Margins: -491.54%
Return on Equity: -71.20%
Return on Assets: -40.14%

Debt:

Current Ratio: 6.15%
Quick Ratio: 6.15%

Misc:

Average Volume: 529,568 shs.
Beta: 1.93
Short Ratio: 13.43

Frequently Asked Questions for Agios Pharmaceuticals (NASDAQ:AGIO)

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.80) by $0.24. The business earned $10.51 million during the quarter, compared to analyst estimates of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The firm's revenue was down 66.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.64) EPS. View Agios Pharmaceuticals' Earnings History.

When will Agios Pharmaceuticals make its next earnings announcement?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Agios Pharmaceuticals.

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?

11 brokers have issued 1-year target prices for Agios Pharmaceuticals' shares. Their predictions range from $45.00 to $90.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $62.88 in the next year. View Analyst Ratings for Agios Pharmaceuticals.

What are analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

1. Cann analysts commented, "This dinner and discussion with management, experts, and investors offered an update on AG-120 and an in-depth look at AG-221. Takeaways for AG-221 focused on outcomes and commercial use. AG-221 was found to have remarkable outcomes, especially in light of the difficult-to-treat population in the study. The enthusiasm expressed by Drs." (6/11/2017)
2. According to Zacks Investment Research, "Agios's shares have outperformed the Medical-Products industry so far this year. As a development-stage company, Agios depends heavily on Celgene for revenues. However, the collaboration with Celgene is encouraging as it provides Agios funds in the form of upfront, regulatory and commercial milestone payments plus royalties. In terms of the company’s pipeline, most of the candidates are in mid and early stages of development and thus, several years away from entering the market. Moreover, the decision to discontinue the development of AG-519 is disappointing. Stiff competition is another matter of concern for the company. Estimates have been going down lately ahead of the company’s Q1 earnings release. The company has mixed record of earnings surprises in recent quarters." (4/28/2017)
3. Cowen and Company analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)

Who are some of Agios Pharmaceuticals' key competitors?

Some companies that are related to Agios Pharmaceuticals include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE), China Biologic Products (CBPO), AveXis (AVXS), Prothena Corporation PLC (PRTA), Axovant Sciences (AXON), Sarepta Therapeutics (SRPT), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Radius Health (RDUS), Aerie Pharmaceuticals (AERI) and Lexicon Pharmaceuticals (LXRX).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

David P. Schenkein M.D., President, Chief Executive Officer, Director
Andrew Hirsch, Chief Financial Officer
Scott Biller Ph.D., Chief Scientific Officer
Christopher Bowden M.D., Chief Medical Officer
Steven L. Hoerter, Chief Commercial Officer
Lewis Clayton Cantley Ph.D., Director
David Scadden M.D., Director
Paul J. Clancy, Independent Director
Ian T. Clark, Independent Director
Kaye I. Foster-Cheek, Independent Director

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Handelsbanken Fonder AB (0.21%), Hamilton Lane Advisors LLC (0.12%), Handelsinvest Investeringsforvaltning (0.06%), Creative Planning (0.03%), Public Employees Retirement Association of Colorado (0.01%) and Parametrica Management Ltd (0.01%). Company insiders that own Agios Pharmaceuticals stock include Celgene European Investment Co, David P Schenkein, Glenn Goddard, John Duncan Higgons, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Institutional Ownership Trends for Agios Pharmaceuticals.

Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd., Clear Harbor Asset Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Agios Pharmaceuticals stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Insider Buying and Selling for Agios Pharmaceuticals.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Hamilton Lane Advisors LLC, Handelsinvest Investeringsforvaltning, Parametrica Management Ltd, Aperio Group LLC, Public Employees Retirement Association of Colorado and Creative Planning. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $58.12.

MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		177 (Vote Outperform)
Underperform Votes:		181 (Vote Underperform)
Total Votes:		358

MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	4 Hold Ratings, 7 Buy Ratings
Consensus Rating:	Buy (Score: 2.64)
Consensus Price Target:	$62.88 (8.18% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
6/26/2017	Janney Montgomery Scott	Downgrade	Buy -> Neutral		High
6/11/2017	Oppenheimer Holdings, Inc.	Set Price Target	Buy	$75.00	Medium
6/11/2017	Cann	Reiterated Rating	Buy	$75.00	Medium
5/18/2017	Canaccord Genuity	Set Price Target	Buy	$90.00	Medium
4/18/2017	Credit Suisse Group	Reiterated Rating	Outperform	$61.00	High
2/16/2017	Cowen and Company	Reiterated Rating	Buy		N/A
1/17/2017	CIBC	Upgrade	Market Perform -> Outperform		N/A
12/19/2016	Leerink Swann	Reiterated Rating	Market Perform	$56.00 -> $45.00	N/A
12/16/2016	Needham & Company LLC	Reiterated Rating	Buy	$60.00 -> $54.00	N/A
8/19/2016	BTIG Research	Initiated Coverage	Neutral		N/A
8/10/2016	Goldman Sachs Group, Inc. (The)	Reiterated Rating	Neutral	$46.00	N/A
6/13/2016	J P Morgan Chase & Co	Upgrade	Neutral -> Overweight	$50.00 -> $62.00	N/A
5/18/2016	SunTrust Banks, Inc.	Boost Price Target	Buy	$57.00 -> $65.00	N/A
11/9/2015	Roth Capital	Lower Price Target	Neutral	$114.00 -> $75.00	N/A

(Data available from 7/26/2015 forward)

Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Earnings History by Quarter for Agios Pharmaceuticals (NASDAQ AGIO)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/2/2017		($1.56)					N/A
5/4/2017	Q1 2017	($1.80)	($1.56)	$9.65 million	$10.51 million	View	Listen
2/16/2017	Q416	($1.51)	($1.34)	$10.89 million	$22.65 million	View	Listen
11/3/2016	Q316	($1.52)	($1.63)	$7.82 million	$8.98 million	View	Listen
8/4/2016	Q216	($0.48)	($1.47)	$39.62 million	$6.98 million	View	Listen
5/5/2016	Q116	($0.79)	($0.61)	$20.94 million	$31.30 million	View	Listen
2/18/2016	Q415	($0.27)	($1.08)	$28.78 million	$6.22 million	View	Listen
11/5/2015	Q315	($0.89)	($1.07)	$17.21 million	$5.80 million	View	Listen
8/6/2015	Q215	($0.46)	($0.85)	$25.75 million	$13.20 million	View	Listen
5/7/2015	Q115	($0.86)	($0.13)	$10.86 million	$34.20 million	View	Listen
2/17/2015	Q414	($0.55)	($0.76)	$10.94 million	$14.64 million	View	Listen
11/7/2014	Q314	($0.53)	$0.10	$8.45 million	$33.90 million	View	Listen
8/7/2014	Q2	($0.47)	($0.54)	$11.00 million	$8.41 million	View	Listen
5/8/2014	Q1	($0.37)	($0.39)	$7.19 million	$8.41 million	View	Listen
3/6/2014	Q4	($0.34)	($0.40)	$6.19 million	$6.70 million	View	Listen
11/7/2013		($0.28)	($0.47)			View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

2017 EPS Consensus Estimate: ($7.60)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	3	($1.86)	($1.78)	($1.81)
Q2 2017	3	($1.92)	($1.80)	($1.88)
Q3 2017	2	($1.98)	($1.96)	($1.97)
Q4 2017	1	($1.95)	($1.95)	($1.95)

(Data provided by Zacks Investment Research)

Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Agios Pharmaceuticals (NASDAQ:AGIO)

Insider Ownership Percentage: 10.55%
Institutional Ownership Percentage: 84.22%

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
7/20/2017	Lewis Clayton Jr. Cantley	Director	Sell	9,000	$56.36	$507,240.00
7/19/2017	Lewis Clayton Jr. Cantley	Director	Sell	3,500	$56.14	$196,490.00
7/7/2017	Scott Biller	Insider	Sell	2,146	$55.00	$118,030.00
7/3/2017	David P Schenkein	CEO	Sell	3,000	$51.18	$153,540.00
6/21/2017	Scott Biller	Insider	Sell	4,292	$55.00	$236,060.00
6/14/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,000	$50.87	$101,740.00
6/7/2017	David P Schenkein	CEO	Sell	3,000	$50.02	$150,060.00
5/25/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$47.10	$95,895.60
5/1/2017	David P Schenkein	CEO	Sell	3,000	$50.06	$150,180.00
4/24/2017	Celgene European Investment Co	Major Shareholder	Buy	624,575	$49.50	$30,916,462.50
4/18/2017	Lewis Clayton Jr. Cantley	Director	Sell	5,090	$54.37	$276,743.30
4/17/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$55.24	$112,468.64
4/3/2017	David P Schenkein	CEO	Sell	3,000	$58.62	$175,860.00
4/3/2017	Scott Biller	Insider	Sell	2,146	$58.03	$124,532.38
3/23/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$53.11	$108,131.96
3/20/2017	Scott Biller	Insider	Sell	6,438	$55.00	$354,090.00
3/6/2017	Robert Nelsen	Director	Sell	40,599	$50.84	$2,064,053.16
2/28/2017	Robert Nelsen	Director	Sell	243,082	$49.36	$11,998,527.52
2/23/2017	Robert Nelsen	Director	Sell	135,364	$49.37	$6,682,920.68
2/16/2017	David P Schenkein	CEO	Sell	6,000	$50.01	$300,060.00
10/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$48.94	$122,545.76
10/5/2016	Scott Biller	Insider	Sell	5,000	$55.00	$275,000.00
9/28/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$54.00	$33,858.00
9/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$54.15	$33,952.05
9/20/2016	Scott Biller	Insider	Sell	5,000	$50.00	$250,000.00
8/30/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$36.81	$23,079.87
8/29/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$37.81	$23,706.87
7/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$42.80	$107,171.20
7/25/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$41.85	$26,239.95
6/28/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$41.88	$104,867.52
6/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$40.37	$25,311.99
6/8/2016	Scott Biller	Insider	Sell	27,500	$65.00	$1,787,500.00
5/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$51.69	$129,431.76
4/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$53.44	$133,813.76
4/25/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$55.00	$34,485.00
3/30/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$37.19	$93,123.76
2/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$37.90	$94,901.60
1/29/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$42.93	$107,496.72
12/29/2015	Lewis Clayton Jr. Cantley	Director	Sell	10,664	$64.93	$692,413.52
12/15/2015	John Duncan Higgons	COO	Sell	20,000	$50.09	$1,001,800.00
11/17/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,408	$59.83	$562,880.64
11/16/2015	John Duncan Higgons	COO	Sell	20,000	$61.51	$1,230,200.00
11/2/2015	Scott Biller	insider	Sell	5,500	$77.12	$424,160.00
10/23/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$61.16	$593,496.64
10/15/2015	John Duncan Higgons	COO	Sell	20,000	$71.04	$1,420,800.00
9/30/2015	Scott Biller	insider	Sell	5,500	$70.44	$387,420.00
9/25/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$83.25	$807,858.00
9/24/2015	Glenn Goddard	SVP	Sell	6,000	$85.97	$515,820.00
9/15/2015	John Duncan Higgons	COO	Sell	20,000	$91.11	$1,822,200.00
8/18/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$94.94	$921,297.76
8/17/2015	John Duncan Higgons	COO	Sell	20,000	$92.24	$1,844,800.00
7/23/2015	Glenn Goddard	SVP	Sell	7,000	$120.45	$843,150.00
7/20/2015	Scott Biller	Insider	Sell	5,500	$113.87	$626,285.00
7/17/2015	Glenn Goddard	SVP	Sell	13,000	$113.71	$1,478,230.00
7/16/2015	John Duncan Higgons	COO	Sell	20,000	$114.02	$2,280,400.00
7/16/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$114.28	$1,108,973.12
6/25/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$105.13	$1,020,181.52
6/15/2015	John Duncan Higgons	COO	Sell	7,000	$105.23	$736,610.00
6/8/2015	Scott Biller	Insider	Sell	5,500	$121.85	$670,175.00
6/1/2015	Christopher Bowden	Insider	Sell	5,000	$120.67	$603,350.00
6/1/2015	David P Schenkein	CEO	Sell	13,000	$120.67	$1,568,710.00
5/27/2015	David P Schenkein	CEO	Sell	8,929	$120.05	$1,071,926.45
5/27/2015	Glenn Goddard	SVP	Sell	2,171	$120.05	$260,628.55
5/20/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$116.64	$1,131,874.56
5/15/2015	John Duncan Higgons	COO	Sell	7,417	$112.89	$837,305.13
5/12/2015	David P Schenkein	CEO	Sell	5,200	$110.02	$572,104.00
5/8/2015	David P Schenkein	CEO	Sell	3,900	$101.32	$395,148.00
5/7/2015	Scott Biller	Insider	Sell	5,500	$96.32	$529,760.00
4/24/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$105.15	$1,020,375.60
4/15/2015	John Duncan Higgons	COO	Sell	6,583	$99.54	$655,271.82
4/13/2015	David P Schenkein	CEO	Sell	3,900	$100.03	$390,117.00
4/8/2015	Scott Biller	Insider	Sell	5,500	$97.64	$537,020.00
4/1/2015	David P Schenkein	CEO	Sell	3,900	$92.54	$360,906.00
3/27/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$93.58	$908,100.32
3/16/2015	Glenn Goddard	SVP	Sell	10,000	$106.24	$1,062,400.00
3/16/2015	John Duncan Higgons	COO	Sell	7,000	$106.24	$743,680.00
3/16/2015	Scott Biller	Insider	Sell	5,500	$106.81	$587,455.00
3/2/2015	David P Schenkein	CEO	Sell	7,800	$107.05	$834,990.00
2/13/2015	David P Schenkein	CEO	Sell	1,471	$120.22	$176,843.62
2/13/2015	Glenn Goddard	SVP	Sell	1,316	$120.31	$158,327.96
2/11/2015	Glenn Goddard	SVP	Sell	16,513	$107.12	$1,768,872.56
2/9/2015	Glenn Goddard	SVP	Sell	15,000	$105.81	$1,587,150.00
2/2/2015	David P Schenkein	CEO	Sell	10,400	$114.31	$1,188,824.00
1/2/2015	David P Schenkein	CEO	Sell	13,000	$110.08	$1,431,040.00
1/2/2015	John Duncan Higgons	COO	Sell	12,000	$110.08	$1,320,960.00
1/2/2015	Scott Biller	Insider	Sell	4,500	$110.08	$495,360.00
12/16/2014	Celgene European Investment Co	Major Shareholder	Buy	228,645	$110.75	$25,322,433.75
12/16/2014	John Maraganore	Director	Buy	1,806	$110.75	$200,014.50
12/1/2014	David P Schenkein	CEO	Sell	13,000	$97.03	$1,261,390.00
12/1/2014	John Duncan Higgons	COO	Sell	12,000	$97.03	$1,164,360.00
12/1/2014	Scott Biller	Insider	Sell	4,500	$97.03	$436,635.00
11/3/2014	Glenn Goddard	SVP	Sell	2,000	$81.71	$163,420.00
11/3/2014	John Duncan Higgons	COO	Sell	13,000	$81.71	$1,062,230.00
11/3/2014	Scott Biller	Insider	Sell	4,500	$81.71	$367,695.00
10/1/2014	Glenn Goddard	SVP	Sell	1,500	$60.07	$90,105.00
10/1/2014	John Duncan Higgons	COO	Sell	13,000	$60.07	$780,910.00
10/1/2014	Scott Biller	Insider	Sell	4,500	$60.07	$270,315.00
9/26/2014	David P Schenkein	CEO	Sell	60,000	$62.68	$3,760,800.00
9/26/2014	Glenn Goddard	SVP	Sell	17,500	$56.53	$989,275.00
9/19/2014	Scott Biller	Insider	Sell	37,996	$50.45	$1,916,898.20
9/2/2014	Glenn Goddard	SVP	Sell	10,000	$46.30	$463,000.00
9/2/2014	John Duncan Higgons	COO	Sell	13,000	$46.30	$601,900.00
9/2/2014	Scott Biller	Insider	Sell	4,500	$46.30	$208,350.00
8/26/2014	John Duncan Higgons	COO	Sell	5,000	$45.05	$225,250.00
8/11/2014	David P Schenkein	CEO	Sell	4,530	$40.17	$181,970.10
7/1/2014	David P Schenkein	CEO	Sell	13,000	$46.52	$604,760.00
7/1/2014	Glenn Goddard	SVP	Sell	3,500	$46.52	$162,820.00
7/1/2014	John Duncan Higgons	COO	Sell	12,000	$46.52	$558,240.00
7/1/2014	Scott Biller	Insider	Sell	4,500	$46.52	$209,340.00
6/23/2014	John Maraganore	Director	Buy	2,300	$43.98	$101,154.00
6/20/2014	Scott Biller	Insider	Sell	2,004	$50.05	$100,300.20
6/13/2014	John Duncan Higgons	COO	Sell	5,000	$45.27	$226,350.00
6/3/2014	John Duncan Higgons	COO	Sell	7,000	$34.47	$241,290.00
5/6/2014	John Duncan Higgons	COO	Sell	5,000	$45.73	$228,650.00
5/1/2014	Glenn Goddard	SVP	Sell	2,000	$42.39	$84,780.00
5/1/2014	John Duncan Higgons	COO	Sell	7,000	$42.39	$296,730.00
5/1/2014	Scott Biller	Insider	Sell	4,500	$42.39	$190,755.00
4/29/2014	Celgene European Investment Co	major shareholder	Buy	294,800	$44.00	$12,971,200.00
4/29/2014	John Maraganore	Director	Buy	2,250	$44.00	$99,000.00
4/7/2014	Glenn Goddard	SVP	Sell	2,000	$45.17	$90,340.00
4/7/2014	John Duncan Higgons	COO	Sell	3,000	$45.17	$135,510.00
4/1/2014	Glenn Goddard	SVP	Sell	4,000	$38.08	$152,320.00
4/1/2014	John Duncan Higgons	COO	Sell	12,000	$38.08	$456,960.00
4/1/2014	Scott Biller	Insider	Sell	4,500	$38.08	$171,360.00
3/7/2014	Glenn Goddard	SVP	Sell	17,468	$42.11	$735,577.48
3/7/2014	John Duncan Higgons	COO	Sell	14,646	$41.41	$606,490.86
3/3/2014	John Duncan Higgons	COO	Sell	8,000	$29.85	$238,800.00
3/3/2014	Scott Biller	Insider	Sell	6,000	$29.85	$179,100.00
2/10/2014	Glenn Goddard	SVP	Sell	6,000	$30.44	$182,640.00
1/27/2014	Glenn Goddard	SVP	Sell	7,000	$26.29	$184,030.00
1/21/2014	Glenn Goddard	SVP	Sell	10,000	$34.71	$347,100.00
7/29/2013	Celgene European Investment Co	Major Shareholder	Buy	708,333	$18.00	$12,749,994.00

(Data available from 1/1/2013 forward)

Headline Trends for Agios Pharmaceuticals (NASDAQ:AGIO) Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)

Source:

Date	Headline
	Commit To Purchase Agios Pharmaceuticals At $45, Earn 10.9% Annualized Using Options - Nasdaq www.nasdaq.com - July 26 at 3:38 PM
	What's in Store for Agios Pharma (AGIO) in Q2 Earnings? finance.yahoo.com - July 26 at 3:38 PM
	Agios Pharmaceuticals, Inc. (AGIO) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - July 26 at 7:12 AM
	Agios Pharmaceuticals, Inc. (AGIO) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - July 24 at 12:11 PM
	Agios Pharmaceuticals, Inc. (AGIO) Director Sells $196,490.00 in Stock www.americanbankingnews.com - July 21 at 7:31 PM
	Insider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Sells 9,000 Shares of Stock www.americanbankingnews.com - July 21 at 7:30 PM
	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Upgraded to "Buy" by BidaskClub www.americanbankingnews.com - July 16 at 4:00 PM
	Zacks: Brokerages Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $11.52 Million www.americanbankingnews.com - July 16 at 8:16 AM
	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expected to Announce Earnings of -$1.52 Per Share www.americanbankingnews.com - July 14 at 4:48 PM
	Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO - Business Wire (press release) www.businesswire.com - July 12 at 4:03 PM
	Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO finance.yahoo.com - July 12 at 4:03 PM
	Insider Selling: Agios Pharmaceuticals, Inc. (AGIO) Insider Sells 2,146 Shares of Stock www.americanbankingnews.com - July 11 at 8:20 PM
	David P. Schenkein Sells 3,000 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock www.americanbankingnews.com - July 6 at 8:04 PM
	Agios/Celgene's Leukemia Candidate Positive in Phase I/II www.zacks.com - June 27 at 8:30 PM
	Agios/Celgene's Leukemia Candidate Positive in Phase I/II - Nasdaq www.nasdaq.com - June 27 at 3:29 PM
	Agios/Celgene's Leukemia Candidate Positive in Phase I/II finance.yahoo.com - June 27 at 3:29 PM
	Agios Pharmaceuticals, Inc. (AGIO) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - June 27 at 12:34 PM
	Mid-Morning Market Update: Markets Open Higher; Durable-Goods Orders Fall 1.1% - Benzinga www.benzinga.com - June 26 at 8:55 PM
	12 Biggest Mid-Day Losers For Monday \| Benzinga - Benzinga www.benzinga.com - June 26 at 8:55 PM
	Mid-Morning Market Update: Markets Open Higher; Durable-Goods Orders Fall 1.1% www.nasdaq.com - June 26 at 3:53 PM
	Agio Pharma Sinks on Midstage Trial finance.yahoo.com - June 26 at 3:53 PM
	Biotech Rally Stumbles As These Small Caps Pull Back finance.yahoo.com - June 26 at 3:53 PM
	Agios Pharmaceuticals, Inc. (AGIO) Cut to Neutral at Janney Montgomery Scott www.americanbankingnews.com - June 26 at 12:16 PM
	Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating ... www.globenewswire.com - June 25 at 8:35 PM
	Agios Pharmaceuticals, Inc. (AGIO) Upgraded to Hold by ValuEngine www.americanbankingnews.com - June 25 at 12:10 AM
	Agios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as ... - Benzinga www.benzinga.com - June 24 at 8:26 PM
	Agios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as First Disease-modifying Treatment for Patients with PKR #EHA2017 finance.yahoo.com - June 24 at 8:26 PM
	Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as the First ... - GlobeNewswire (press release) globenewswire.com - June 24 at 3:25 PM
	Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency finance.yahoo.com - June 24 at 3:24 PM
	New Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML finance.yahoo.com - June 24 at 3:24 PM
	Scott Biller Sells 4,292 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock www.americanbankingnews.com - June 23 at 7:32 PM
	Celgene: I Don't Necessarily Understand The Science, But I Love The Numbers - Seeking Alpha seekingalpha.com - June 22 at 3:23 PM
	Agios Pharmaceuticals, Inc. (AGIO) Expected to Post Quarterly Sales of $11.52 Million www.americanbankingnews.com - June 22 at 10:35 AM
	Myelodysplastic Syndrome Pipeline Therapeutic Drugs and ... - MarketWatch www.marketwatch.com - June 21 at 2:09 AM
	-$1.52 EPS Expected for Agios Pharmaceuticals, Inc. (AGIO) This Quarter www.americanbankingnews.com - June 20 at 2:24 PM
	Agios Pharmaceuticals, Inc. (AGIO) Director Sells $101,740.00 in Stock www.americanbankingnews.com - June 15 at 7:42 PM
	ETFs with exposure to Agios Pharmaceuticals, Inc. : June 15, 2017 finance.yahoo.com - June 15 at 4:59 PM
	Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : June 14, 2017 finance.yahoo.com - June 14 at 3:25 PM
	Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : June 13, 2017 finance.yahoo.com - June 13 at 11:38 AM
	Agios Pharmaceuticals, Inc. (AGIO) PT Set at $75.00 by Oppenheimer Holdings, Inc. www.americanbankingnews.com - June 11 at 11:32 PM
	Agios Pharmaceuticals' (AGIO) "Buy" Rating Reaffirmed at Cann www.americanbankingnews.com - June 11 at 9:34 PM
	Insider Selling: Agios Pharmaceuticals Inc (AGIO) CEO Sells 3,000 Shares of Stock www.americanbankingnews.com - June 8 at 7:52 PM
	Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue? - Nasdaq www.nasdaq.com - June 8 at 8:01 AM
	Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue? finance.yahoo.com - June 8 at 8:00 AM
	Celgene and Agios Announce Data on Idhifa for Leukemia finance.yahoo.com - June 7 at 3:30 PM
	Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 ... www.businesswire.com - June 7 at 5:13 AM
	Celgene (CELG) & Agios Pharmaceuticals (AGIO) Presents Updated Data from Phase 1 Trial of Oral IDHIFA (Enasidenib) www.streetinsider.com - June 7 at 5:13 AM
	BRIEF-Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30 www.reuters.com - June 7 at 5:13 AM
	BRIEF-Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30 - Reuters www.reuters.com - June 6 at 3:37 PM
	Celgene (CELG) & Agios Pharmaceuticals (AGIO) Presents Updated ... - StreetInsider.com www.streetinsider.com - June 6 at 3:37 PM